Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
About this trial
This is an interventional treatment trial for Epithelial Ovarian Cancer focused on measuring ovarian neoplasms, randomized controlled trial, paclitaxel, carboplatin
Eligibility Criteria
Inclusion Criteria: Histologically confirmed stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer No prior chemotherapy Age: 20 and more Performance status: ECOG 0-3 1) Absolute neutrophil count at least 1,500/mm3 2) Platelet count at least 100,000/mm3 3) Bilirubin less than 1.5mg/dL 4) SGOT less than 100 IU/l 5) Serum creatinine less than 1.5mg/dL Written informed consent Exclusion Criteria: Patients with ovarian borderline tumor Patients who have any evidence of the other cancer present within the last 5 years with the exception of carcinoma in situ or intramucosal cancer that is curable with local therapy Patients with active infection or uncontrolled diabetes Patients with unstable angina, or those who have had a myocardial infarction within the past 6 months, or patients with serious arrythmia that requires medication Patients who have a history of hypersensitivity to polyoxyethylated castor oil (Cremophor EL)
Sites / Locations
- National Cancer Center Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
1
2
Drug: Paclitaxel 180mg/m2+CBDCA AUC6 q21 days x 6-9cycles
Drug: Paclitaxel 80mg/m2 weekly +CBDCA AUC6 q21 days x 6-9cycles